Potential use of quantitative tissue phenotype to predict malignant risk for oral premalignant lesions.

Martial Guillaud, Lewei Zhang, Catherine Poh, Miriam P Rosin, Calum MacAulay
Author Information
  1. Martial Guillaud: British Columbia Cancer Agency/Cancer Research Center, University of British Columbia, Vancouver, British Columbia, Canada. mguillau@bccrc.ca

Abstract

The importance of early diagnosis in improving mortality and morbidity rates of oral squamous cell carcinoma (SCC) has long been recognized. However, a major challenge for early diagnosis is our limited ability to differentiate oral premalignant lesions (OPL) at high risk of progressing into invasive SCC from those at low risk. We investigated the potential of quantitative tissue phenotype (QTP), measured by high-resolution image analysis, to identify severe dysplasia/carcinoma in situ (CIS; known to have an increased risk of progression) and to predict progression to cancer within hyperplasia or mild/moderate dysplasia. We generated a nuclear phenotype score (NPS), a combination of five nuclear morphometric features that best discriminate 4,027 "normal" nuclei (selected from 29 normal oral biopsies) from 4,298 "abnormal" nuclei (selected from 30 SCC biopsies). This NPS was then determined for a set of 69 OPLs. Severe dysplasia/CIS showed a significant increase in NPS compared with hyperplasia or mild/moderate dysplasia. However, within the latter group, elevated NPS was strongly associated with the presence of high-risk loss of heterozygosity (LOH) patterns. There was a statistical difference between NPS of hyperplasia or mild/moderate dysplasia that progressed to cancer and those that did not. Individuals with a high NPS had a 10-fold increase in relative risk of progression. In the multivariate Cox model, LOH and NPS together were the strongest predictors for cancer development. These data suggest that QTP could be used to identify lesions that require molecular evaluation and should be integrated with such approaches to facilitate the identification of hyperplasia or mild/moderate dysplasia OPLs at high risk of progression.

References

  1. Ann N Y Acad Sci. 2007 Mar;1098:167-83 [PMID: 17332080]
  2. Oral Oncol. 2007 Mar;43(3):224-31 [PMID: 16931119]
  3. Nat Rev Cancer. 2004 Sep;4(9):677-87 [PMID: 15343274]
  4. Cytometry A. 2004 Jul;60(1):81-9 [PMID: 15229860]
  5. Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1087-94 [PMID: 10613341]
  6. Int J Oral Maxillofac Surg. 2002 Apr;31(2):145-53 [PMID: 12102411]
  7. Nat Med. 1996 Jun;2(6):682-5 [PMID: 8640560]
  8. Pathologica. 1995 Jun;87(3):286-99 [PMID: 8570289]
  9. Int J Oral Maxillofac Surg. 1987 Dec;16(6):656-64 [PMID: 3125262]
  10. Oral Surg Oral Med Oral Pathol. 1972 Mar;33(3):389-99 [PMID: 4501168]
  11. Cytometry A. 2005;63(1):34-40 [PMID: 15614828]
  12. Anal Quant Cytol Histol. 1990 Jun;12(3):165-71 [PMID: 2369469]
  13. J Cell Biochem Suppl. 2000;Suppl 35:151-7 [PMID: 11389545]
  14. Cell Oncol. 2004;26(3):101-17 [PMID: 15371646]
  15. Oral Oncol. 1998 Mar;34(2):77-83 [PMID: 9682768]
  16. Cell Oncol. 2007;29(1):47-58 [PMID: 17429141]
  17. N Engl J Med. 2001 Apr 26;344(17):1323-6 [PMID: 11320393]
  18. Anal Cell Pathol. 2003;25(1):1-36 [PMID: 12590175]
  19. J Oral Pathol Med. 1995 May;24(5):198-200 [PMID: 7616457]
  20. Cancer Res. 1996 Jun 1;56(11):2488-92 [PMID: 8653682]
  21. Int J Oncol. 2003 Dec;23(6):1607-13 [PMID: 14612933]
  22. Anal Cell Pathol. 2003;25(3):129-38 [PMID: 12775917]
  23. Cancer. 1984 Feb 1;53(3):563-8 [PMID: 6537892]
  24. J Pathol. 1998 Apr;184(4):360-8 [PMID: 9664901]
  25. Comput Methods Programs Biomed. 2005 Feb;77(2):99-113 [PMID: 15652632]
  26. Nat Rev Cancer. 2002 Mar;2(3):210-9 [PMID: 11990857]
  27. J Pathol. 2000 Mar;190(4):462-9 [PMID: 10699996]
  28. Anal Cell Pathol. 2001;23(2):89-95 [PMID: 11904464]
  29. Head Neck. 2004 Apr;26(4):345-52 [PMID: 15054738]
  30. Clin Cancer Res. 2000 Feb;6(2):357-62 [PMID: 10690511]
  31. Anal Cell Pathol. 1998;16(1):11-27 [PMID: 9584897]

Grants

  1. R01 DE013124/NIDCR NIH HHS
  2. R01 DE017013/NIDCR NIH HHS
  3. R01 DE017013-03/NIDCR NIH HHS
  4. R01 DE13124/NIDCR NIH HHS

MeSH Term

Carcinoma, Squamous Cell
Diagnostic Techniques and Procedures
Disease Progression
Early Diagnosis
Humans
Loss of Heterozygosity
Mouth Neoplasms
Phenotype
Precancerous Conditions
Prognosis
Regression Analysis
Risk Factors
Sensitivity and Specificity
Time Factors

Word Cloud

Created with Highcharts 10.0.0NPSriskoralprogressionhyperplasiamild/moderatedysplasiaSCClesionshighphenotypecancerearlydiagnosisHoweverpremalignantquantitativetissueQTPidentifypredictwithinnuclear4nucleiselectedbiopsiesOPLsincreaseLOHimportanceimprovingmortalitymorbidityratessquamouscellcarcinomalongrecognizedmajorchallengelimitedabilitydifferentiateOPLprogressinginvasivelowinvestigatedpotentialmeasuredhigh-resolutionimageanalysisseveredysplasia/carcinomasituCISknownincreasedgeneratedscorecombinationfivemorphometricfeaturesbestdiscriminate027"normal"29normal298"abnormal"30determinedset69Severedysplasia/CISshowedsignificantcomparedlattergroupelevatedstronglyassociatedpresencehigh-risklossheterozygositypatternsstatisticaldifferenceprogressedIndividuals10-foldrelativemultivariateCoxmodeltogetherstrongestpredictorsdevelopmentdatasuggestusedrequiremolecularevaluationintegratedapproachesfacilitateidentificationPotentialusemalignant

Similar Articles

Cited By